About Biotie
Biotie is a company based in Turku (Finland) founded in 1998 was acquired by Acorda in January 2016. Biotie has raised $149.81 million across 4 funding rounds from investors including Acorda and The Baupost Group. The company has 27 employees. Biotie has completed 2 acquisitions, including Elbion and Synosia Therapeutics. Biotie operates in a competitive market with competitors including Indivior, Ethypharm, Braeburn, Amygdala Neurosciences and Cessation Therapeutics, among others.
- Headquarter Turku, Finland
- Employees 27
- Stage Public
- SectorsHealthcare
- Website biotie.com
- Social LinkedIn X
- Acquired by Acorda (Jan 2016)
Funding Insights of Biotie
Biotie has successfully raised a total of $149.81M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $149.81M
- Total Rounds 4
- First Round $143.75M
(Jun 2013)
- Investors Count 1
All 4 funding rounds of Biotie with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2015 | – | Post-IPO | – | – | |
| May 2015 | $6.06M | Series D | – | – | – |
| Jul 2014 | $2M | Grant | – | – | – |
| Jun 2013 | $143.75M | Series D | – | – | – |
2 investors in total: 2 institutional.
Investors in Biotie
Biotie has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Acorda and The Baupost Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Conducts long-term value-oriented investments for families, foundations, and institutions. | 1982 | baupost.com | Boston, United States | |
Engaged in the development and commercialization of therapies that improve neurological function. | 1995 | acorda.com | Ardsley, United States |
Investor details for Biotie
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biotie
1 people are tracked at Biotie (1 in leadership); the tracked headcount is 27.
| Name | Role | Group |
|---|---|---|
Jari Saarinen | CEO | Leadership |
Complete people profiles for Biotie
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biotie
Biotie has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Elbion and Synosia Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics for CNS disorders including Parkinson's are developed. | synosia.com | Basel, Switzerland | 2005 | Jan 2011 | $121.5M | |
Small molecules for CNS and inflammatory diseases were discovered. | elbion.com | Radebeul, Germany | 2002 | Nov 2008 | •••• |
Complete acquisition details for Biotie
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Biotie
7 dated milestones of Biotie across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Biotie is founded.
- Acquisition Acquires Elbion.
- Acquisition Acquires Synosia Therapeutics.
- Funding First funding round of $143.8M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
- Exit Acquired by Acorda.
Competitors of Biotie
Biotie operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indivior, Ethypharm, Braeburn, Amygdala Neurosciences and Cessation Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indivior.com | 2014 | Richmond Hill, United States | – | 1,051 | Therapeutics for opioid addiction treatment are developed and commercialized. | |
| ethypharm.com | 1977 | Saint Cloud, France | $248.09M | – | Therapies for pain and addiction treatment are developed. | |
| braeburnrx.com | 2012 | Philadelphia, United States | $110M | – | Long-acting therapies for opioid addiction and chronic pain are developed. | |
| amygns.com | 2015 | San Francisco, United States | $7.05M | – | Therapies for substance use disorders are developed by Amygdala Neurosciences. | |
| cessationtherapeutics.com | 2017 | San Jose, United States | $6.76M | – | Developer of immunotherapy based vaccines to manage addictions | |
| aelisfarma.com | 2013 | Bordeaux, France | $14.04M | – | Developer of small molecule drugs targeting CB1 receptor for CNS diseases | |
| titanpharm.com | 1992 | San Francisco, United States | – | 11 | A specialty pharmaceutical company developing proprietary therapeutics for select chronic diseases | |
| orexo.com | 1995 | Uppsala, Sweden | – | – | Therapeutics for mental illness and substance use disorders are developed. | |
| 4p-pharma.com | 2014 | Lille, France | $18.49M | – | French Biotech startup that develops to clinical trial stage the molecules it has in-licensed |
Detailed competitors of Biotie
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biotie
Complete news archive for Biotie
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Biotie
10 companies that operate in the same segment as Biotie (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Biotie
Biotie was founded in 1998 and raised its 1st funding round 15 years after it was founded.
Biotie is headquartered in Turku, Finland. It is registered at Turku, Varsinais-suomi, Finland.
Jari Saarinen is the current CEO of Biotie.
Biotie is a funded company, having raised a total of $149.81M across 4 funding rounds to date. The company's 1st funding round was a Series D of $143.75M, raised on Jun 2013.
Biotie has 27 employees.
Biotie was founded in 1998 in Turku, Finland, as a biotech firm specializing in drug development for central nervous system disorders. Operations center on advancing treatments for neurodegenerative and psychiatric conditions, including Selincro for alcohol dependency, which is marketed in Europe by H. Lundbeck AS, and Tozadenant, now entering Phase 3 trials for Parkinsons disease. The company operates in the commercial stage of biotechnology.
Biotie's top competitors include Indivior, Ethypharm and Amygdala Neurosciences.
Biotie has made 2 acquisitions, including Elbion, and Synosia Therapeutics.
Biotie has 2 investors. Key investors include Acorda, and The Baupost Group.
Yes. Biotie was acquired by Acorda in January 2016.